Epidemiology of Rh Hemolytic Disease of the Newborn in the United States

JAMA: The Journal of the American Medical Association

Volumn 265, Issue 24, 1991, Pages 3270-3274

  Chávez, Gilberto F ^a,b   Mulinare, Joseph ^a   Edmonds, Larry D ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PRIORITY JOURNAL; UNITED STATES;

ADULT; ERYTHROBLASTOSIS, FETAL; FEMALE; HUMAN; INCIDENCE; INFANT, NEWBORN; MALE; MATERNAL AGE; PARITY; POPULATION SURVEILLANCE; RH-HR BLOOD-GROUP SYSTEM; UNITED STATES;

EID: 0025860203     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03460240066029     Document Type: Article

References (27)

1. Behrman RE, Vaughan III VC. Nelson Textbook of Pediatrics. 12th ed. Philadelphia, Pa: WB Saunders Co; 1987:384-388.
2. Freda VJ, Gorman JG, Pollack W, Bowe E. Prevention of Rh hemolytic diseases: 10 years’ clinical experience with Rh immune globulin. N Engl J Med. 1975;292:1014-1016.
3. Grimes DA, Ross WC, Hatcher RA. Rh immunoglobulin utilization after spontaneous and induced abortion. Obstet Gynecol. 1977;50:261-263.
4. Grimes DA, Geary FH, Hatcher RA. Rh immunoglobulin utilization after ectopic pregnancy. Am J Obstet Gynecol. 1981;140:246-249.
5. Henry G, Wexler P, Robinson A. Rh-immune globulin after amniocentesis for genetic diagnosis. Obstet Gynecol. 1976;48:557-559.
6. Grimes DA, Steele AO, Hatcher RA. Rh immunoglobulin use with placenta previa and abruptio placentae. South Med J. 1983;76:743-746.
7. Frigoletto FD, Umansky I. Erythroblastosis fetalis: identification, management, and prevention. Clin Perinatol. 1979;6:321-330.
8. Adams MM, Marks JS, Koplan JP. Cost implications of routine antenatal administration of Rh immune globulin. Am J Obstet Gynecol. 1984;149:633-638.
9. Caiola G. Efforts should be made to eradicate Rh hemolytic diseases of the fetus and newborn. Obstet Gynecol Surv. 1984;39(suppl 1):55-57.
10. US Preventive Services Task Force. Guide to Clinical Preventive Services: An Assessment of the Effectiveness of 169 Interventions. 1st ed. Baltimore, Md: Williams & Wilkins; 1989:221-224.
11. Bowman JM, Pollock J. Rh immunization in Manitoba: progress in prevention and management. Can Med Assoc J. 1983;129:343-345.
12. Bowman JM. Prevention of Rhesus isoimmunization. Am J Obstet Gynecol. 1984;148:1151-1152.
13. Wysowski DK, Flynt JW, Goldberg MF, Connell FA. Rh hemolytic disease: epidemiologic surveillance in the United States 1968-1975. JAMA. 1979;242:1376-1379.
14. Centers for Disease Control. Rh hemolytic disease: Connecticut, United States, 1970-1979. MMWR. 1981;30:13-15.
15. Centers for Disease Control. Temporal trends in the incidence of malformations in the United States, selected years, 1970-71, 1982-83. MMWR. 1985;34:1SS-3SS.
16. Edmonds LD, Layde PM, James LM, Flynt JW, Erickson JD, Oakley GP. Congenital malformations surveillance: two American systems. Int J Epidemiol. 1981;10:247-252.
17. Clarke CA, Mollison PL, Whitfield AGW. Deaths from rhesus haemolytic disease in England and Wales in 1982 and 1983. BMJ. 1985;291:17-19.
18. Advance Report of Final Natality Statistics, 1986. Hyattsville, MD: National Center for Health Statistics; 1988. US Dept of Health and Human Services publication PHS 88-1120. Monthly Vital Statistics Report, vol 37, No. 3.
19. Keith L, Berger GS. Anti-Rh disease prophylaxis: after pregnancy termination, fetomaternal bleed, Rh+ transfusion. Perinatal Care. 1978; 2:37-45.
20. Pollack W, Freda VJ, Gorman JG. 10 years of Rh disease prevention. Perinatal Care. 1978;2:8-13.
21. Bowman JM. Preventing Rh sensitization during pregnancy. Perinatal Care. 1978;2:24-32.
22. Wible-Kant J, Beer AE. Antepartum Rh immune globulin. Clin Perinatol. 1983;10:343-355.
23. Lim OW, Fleisher AA, Ziel HK. Reduction of Rh(D) sensitization: a cost-effective analysis. Obstet Gynecol. 1982;59:477-480.
24. Hensleigh PA. Preventing rhesus isoimmunization. Antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification. Am J Obstet Gynecol. 1983;146:749-755.
25. Kornstad L. Fifteen years’ experience with post-partum Rh prophylaxis in Norway (1969-83): incidence of new cases of anti-D and other clinically important blood group antibodies in pregnant women. NIPH Ann. 1987;10:3-10.
26. Adams MM, Marks JS, Gustafson J, Oakley GP. Rh hemolytic disease of the newborn: using incidence observations to evaluate the use of Rh immune globulin. Am J Public Health. 1981; 71:1031-1035.
27. Centers for Disease Control. Guidelines for evaluating surveillance systems. MMWR. 1988; 37(suppl S-5):1-18.